PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Provectus Biopharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Provectus Biopharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.01M, a 30.7% decline year-over-year.
  • Provectus Biopharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$3.03M, a 4.49% increase year-over-year.
  • Provectus Biopharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$3.1M, a 12.7% increase from 2022.
  • Provectus Biopharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$3.55M, a 35.8% increase from 2021.
  • Provectus Biopharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$5.54M, a 17% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$3.03M -$1.01M -$239K -30.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$2.79M -$847K -$11.8K -1.41% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$2.78M -$504K +$323K +39.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$3.1M -$663K +$69.2K +9.45% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$3.17M -$776K -$62.6K -8.77% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$3.11M -$835K +$243K +22.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$3.35M -$827K +$203K +19.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$3.55M -$733K +$506K +40.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$4.06M -$713K +$338K +32.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$4.4M -$1.08M +$502K +31.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$4.9M -$1.03M +$639K +38.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$5.54M -$1.24M +$433K +25.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$5.97M -$1.05M +$513K +32.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$6.49M -$1.58M +$35.2K +2.18% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$6.52M -$1.67M +$157K +8.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$6.68M -$1.67M -$116K -7.46% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$6.56M -$1.56M +$256K +14% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$6.82M -$1.61M +$563K +25.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$7.38M -$1.83M -$457K -33.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$6.92M -$1.56M +$633K +28.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 -$7.56M -$1.82M -$211K -13.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$7.34M -$2.18M -$721K -49.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$6.62M -$1.37M +$1.53M +52.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$8.15M -$2.19M +$534K +19.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$8.69M -$1.61M +$1.5M +48.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$10.2M -$1.46M +$1.84M +55.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$12M -$2.9M +$1.49M +33.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q4 2017 -$13.5M -$2.72M +$2.28M +45.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$15.8M -$3.11M +$2.76M +47.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$18.6M -$3.29M +$1.75M +34.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$20.3M -$4.39M +$4.12M +48.4% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$24.4M -$5M +$4.65M +48.2% Oct 1, 2016 Dec 31, 2016 10-K 2017-03-31
Q3 2016 -$29.1M -$5.88M -$96.2K -1.67% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$29M -$5.04M -$499K -11% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$28.5M -$8.51M -$3.98M -88% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 -$24.5M -$9.65M -$10.5M -1283% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-31
Q3 2015 -$14M -$5.78M -$2.03M -54.2% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-31
Q2 2015 -$12M -$4.55M -$3.9M -607% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-31
Q1 2015 -$8.1M -$4.53M +$2.14M +32.1% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-31
Q4 2014 -$10.2M $816K +$17.4M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-30
Q3 2014 -$27.7M -$3.75M +$804K +17.7% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-30
Q2 2014 -$28.5M -$643K +$1.74M +73% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-30
Q1 2014 -$30.2M -$6.67M -$2.5M -59.9% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-30
Q4 2013 -$27.7M -$16.6M -$14.7M -764% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$13M -$4.55M -$2.21M -94% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$10.8M -$2.38M +$1.46M +38% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$12.3M -$4.17M +$298K +6.67% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 -$12.6M -$1.92M +$1.53M +44.4% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-13
Q3 2012 -$14.1M -$2.35M +$4.1M +63.6% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-13
Q2 2012 -$18.2M -$3.83M +$702K +15.5% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-13
Q1 2012 -$18.9M -$4.47M +$536K +10.7% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-13
Q4 2011 -$19.4M -$3.45M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-14
Q3 2011 -$6.44M +$465K +6.73% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-14
Q2 2011 -$4.54M -$1.15M -34% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-14
Q1 2011 -$5M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-14
Q3 2010 -$6.91M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$3.38M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.